- Home
- DYN vs GLPG Comparison
DYN vs GLPG Comparison
Compare DYN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYN | GLPG |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DYN | GLPG |
|---|---|---|
| Price | $19.27 | $32.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | ★ $40.25 | $31.33 |
| AVG Volume (30 Days) | ★ 3.2M | 109.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $336,643,201.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $6.36 | $22.36 |
| 52 Week High | $28.96 | $37.78 |
Technical Indicators
Market Signals| Indicator | DYN | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 59.97 |
| Support Level | $18.21 | $31.41 |
| Resistance Level | $23.96 | $31.98 |
| Average True Range (ATR) | 1.55 | 0.50 |
| MACD | -0.30 | 0.20 |
| Stochastic Oscillator | 18.09 | 91.41 |
Price Performance
Historical ComparisonAbout DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.